Physician profile
Eric Bray
NPI 1851910475
$1,637.54
in general payments reported to CMS, 2019-2025
13 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.76 · 2023: $424 · 2024: $914 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $428.09 | 2023-2025 | |
| Dermavant Sciences, INC. | $224.13 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $204.50 | 2023-2024 | Sotyktu |
| Pfizer INC. | $162.29 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $136.24 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $126.31 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.28 | 2023-2024 | Spevigo |
| Abbvie INC. | $76.49 | 2023-2025 | Skyrizi |
| Ucb, INC. | $76.27 | 2023-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $45.89 | 2022-2023 | Oracea, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $31.52 | 2025 | Zoryve |
| Lilly USA, LLC | $24.89 | 2024 | Ebglyss |
| Helsinn Therapeutics (U.S.), INC. | $20.64 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.